Nirvana Life Sciences Inc.
NIRVF
$0.083
$0.0830.00%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.35% | 68.95% | 64.36% | 41.89% | 80.03% |
| Total Depreciation and Amortization | -82.63% | -60.18% | -73.58% | -80.41% | -63.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.81% | -93.50% | -91.22% | -54.91% | -83.78% |
| Change in Net Operating Assets | 162.54% | 84.15% | 42.42% | -7.60% | -85.12% |
| Cash from Operations | 80.82% | 83.78% | 73.04% | 44.02% | -29.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 148.42% | 315.97% | -56.03% | -43.60% | 90.46% |
| Total Debt Repaid | 28.40% | 200.00% | 204.82% | -- | -124.15% |
| Issuance of Common Stock | -- | -100.00% | -91.53% | -19.16% | 113.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | 200.00% | 200.00% | -- | -- |
| Cash from Financing | -129.81% | -82.12% | -83.23% | -43.18% | -5.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,775.00% | -324.24% | -108.09% | 56.21% | 98.52% |